Drug Database
TR

travoprost (Travatan Z / Travantan Z / Travatanz)

✓ Approved

Novartis AG · PTGFR · Small Molecule

What is travoprost?

travoprost is a small molecule developed by Novartis AG. It is approved for therapeutic indications via others.

Drug Profile

Brand NamesTravatan Z, Travantan Z, Travatanz
CompanyNovartis AG
Drug ClassSmall Molecule
Molecular TargetPTGFR
RouteOthers
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Mechanism of Action

Molecular Targets

travoprost acts on 1 molecular target:

PTGFRprostaglandin F receptor (FP)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

travoprost is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Eye disordersGlaucoma✓ Approved

Related Research Articles

PubMedDalton transactions (Cambridge, England : 2003)2026-11-11

Heterometallic iron calix[n]arenes (n = 6, 8): structure and ring opening polymerization capability.

Sun Qi Q, Wright Victoria E VE, Lee Darren S DS, Motuzis Ignas I et al.

A number of interesting iron-containing calix[n]arene (n = 6, 8) species have been isolated from reactions involving either: in situ-generated heterobimetallic iron alkoxides of the type [MFe(Ot-Bu)3] (M = Na, K) and the parent calixarenes (L6H6 = p-tert-butylcalix[6]areneH6 or L8H8 = p-tert-butylcalix[8]areneH8) or, in the case of LdioxaH6 = p-tert-butyltetrahomodioxacalix[6]areneH6, reaction with [Fe(Ot-Bu)2]. Initial reactions involving the use of L6H6/n-BuLi followed by either FeBr2 or FeBr3 led to the isolation of only lithium-containing calix[6]arene complexes, namely [Li8(L6H2)2(H2O)(MeCN)7]·6.5MeCN (1·6.5MeCN), {[(L6H2)Li6(NCMe)2]2(O)2(H2O)2X2}·14MeCN (2·14MeCN; X = 94%OH, 6%Br). However, the use of L6H6/Na[Fe(Ot-Bu)3] led to the isolation of [Fe3.93Na4.07(L6)(L6H2)(O)(OH)(NCMe)7.75]·5.75MeCN (3·5.75MeCN), whilst for LdioxaH6 following reactions with [Fe(OtBu)2], [Fe(NCMe)2(LdioxaH4)]·3MeCN (4·3MeCN) was isolated. In the case of L8H8, the combination with n-BuLi and subsequently FeCl2 led to [(FeCl)2Fe2(μ3-O)2{Li(NCMe)2}2{Li(NCMe)0.691(THF)0.309}2(L8)(Ot-Bu)2] (5), whereas the use of M[Fe(Ot-Bu)3] (M = Na, K) led to the isolation of {Na[(Fe2O(L8)(Na(NCMe))2)2Fe]}·18MeCN (6·18MeCN), [Fe6O4(L8)(L8H2)Na4(NCMe)5(OH2)(OH)][Fe6O4(L8)(L8H2)Na4(NCMe)4(OH2)2(OH)]·Na(NCMe)4·Na·13MeCN (7·Na(NCMe)4·Na·13MeCN), Fe[(L8H4)K3(NCMe)5]2·8MeCN (8·8MeCN) and [(Fe2K2)(O)(NCMe)5(L8H2)]·5.5MeCN (9·5.5MeCN). The molecular structures of 1-9 were determined. These complexes were screened as catalysts for the ring-opening polymerization (ROP) of the cyclic esters ε-caprolactone (ε-CL) and δ-valerolactone (δ-VL) with and without benzyl alcohol (BnOH). For comparison, the precursors M[Fe(Ot-Bu)3] (M = Na, K) were screened under the same conditions. The results revealed that for the ROP of ε-CL, the catalysts generally performed better under air, with kinetic data revealing the trend 9 > 7 > 6 ≈ 3 > 8 > 4 ≈ 5 ≈ 1 ≈ 2. For δ-VL, conversions across all catalytic systems were much higher, with the rate trend 6 > 9 > 7 > 4 > 3 > 8 > 1 ≈ 5 ≈ 2. MALDI-ToF spectra revealed that different families of products were formed, including linear polymers (with end groups H/OH or H/OBn) and cyclic polymers.

PMID 43012172
Read full article →
PubMedJournal of agricultural and food chemistry2026-11-11

Synbiotic of 2'-FL and B. longum subsp. infantis BXY2 Alleviates Colitis in Toddler Microbiota-Associated Mice: Potential Involvement of Gut Microbial Arachidonic Acid Metabolism.

Jing Yizhi Y, Bai Xiaoyue X, Li Junzhu J, Feng Xin X et al.

Increasing inflammatory bowel disease (IBD) incidence in toddlers requires safe interventions. We developed a synbiotic combining 2'-fucosyllactose (2'-FL) with Bifidobacterium strain and evaluated its protective efficacy against DSS-induced colitis in toddler microbiota-associated (TMA) mice. Among 30 Bifidobacterium strains, Bifidobacterium longum subsp. infantis BXY2 and Bifidobacterium. breve BG4 utilized 2'-FL in vitro. However, only the 2'-FL and BXY2 synbiotic significantly alleviated colitis. The 400 mg/kg 2'-FL and BXY2 synbiotic showed the greatest protective effect, restoring body weight and colon length, reducing disease activity and histological scores, improving barrier function, attenuating inflammation. Compared with 2'-FL or BXY2 alone, the synbiotic enhanced goblet cells and barrier proteins. Metagenomics revealed enrichment of B. longum subsp. infantis and Phascolarctobacterium faecium. Metabolomics showed reduced fecal arachidonic acid (AA). These results indicated that gut microbial AA metabolism might be involved in alleviating colitis in TMA mice. Thus, this synbiotic is a promising preventive strategy for toddler IBD.

PMID 43012685
Read full article →
PubMedDiabetes, obesity & metabolism2026-11-11

Association Between Orforglipron and Blood Pressure in Adults With Obesity With or Without Type 2 Diabetes: Post Hoc Analyses From ATTAIN-1 and ATTAIN-2 Trials.

Plat Arian A, Dennehy Ellen B EB, Jouravskaya Irina I, Stefanski Adam A et al.

This post hoc analysis assessed the association between orforglipron and blood pressure in adults with obesity or overweight without (ATTAIN-1) and with Type 2 diabetes (T2D; ATTAIN-2). This study included ATTAIN-1 and ATTAIN-2 participants randomized to receive orforglipron (pooled doses) or placebo. A mixed model of repeated measures was used to assess changes in blood pressure across baseline subgroups at Week 72. The association between weight change and systolic blood pressure (SBP) was evaluated by exploratory mediation analysis. Blood-pressure-related adverse events were also reported. Exploratory subgroup analyses reflected reductions in SBP across all baseline subgroups with no clear evidence of heterogeneity in ATTAIN-1 and ATTAIN-2 (all interaction p > 0.10). Reductions in diastolic blood pressure (DBP) were observed across most of the baseline subgroups in ATTAIN-1, while a greater reduction in DBP was observed among participants with baseline DBP ≥ 80 mmHg compared with those who had baseline DBP < 80 mmHg in ATTAIN-2 (interaction p = 0.002). At Week 72, numerically greater proportions of orforglipron-treated participants achieved study-visit-office normal blood pressure than placebo in ATTAIN-1 and -2. Mediation analysis suggests that 58.3% and 80.8% of the reduction in SBP was estimated to be mediated by orforglipron-induced weight reduction in ATTAIN-1 and -2, respectively (p < 0.001). Low blood pressure-related adverse events were uncommon but more frequent with orforglipron treatment than with placebo, and were mostly mild to moderate in severity. In these post hoc analyses of ATTAIN-1 and -2, reductions in SBP were broadly consistent across baseline subgroups, with no clear evidence of heterogeneity. The changes were estimated to be largely mediated by weight loss, and potential weight-independent effects on blood pressure require further evaluation.

PMID 43010686
Read full article →
PubMedFrontiers in veterinary science2026-11-11

Comparison of the pathogenicity of a Taiwan lineage 1 NADC30/34-like recombinant and a lineage 3 Betaarterivirus suid 2 in pigs.

Lai Yi-Fang YF, Lin Chao-Nan CN, Chiou Ming-Tang MT, Chang Yen-Chen YC et al.

Porcine reproductive and respiratory syndrome virus 2 (PRRSV-2; Betaarterivirus suid 2) causes porcine reproductive and respiratory syndrome, leading to severe economic losses in the global swine industry. Lineage 1 (L1) PRRSV-2 has emerged and become increasingly prevalent in North America and Asia. This study compared the pathogenic characteristics of a Taiwan NADC30/34-like L1 recombinant and a lineage 3 (L3) PRRSV-2 strain and evaluated their suitability for establishing an experimental infection model in growing pigs. Ten-week-old pigs were inoculated with either the NADC30/34-like L1 NPUST-107-844/2018 strain or the L3 SW2018001-YL strain via concurrent intranasal and intramuscular routes. Pigs inoculated with the L1 strain exhibited higher body temperatures and a greater frequency of fever during the early post-inoculation period than those inoculated with the L3 strain. However, no significant differences were observed between the groups in peak viremia, lung pathological scores, or plasma cytokine concentrations. These results indicate that the Taiwan L1 strain induced a more pronounced early febrile response but produced virological, pulmonary pathological, and systemic cytokine responses comparable to those induced by the Taiwan L3 strain. Collectively, these findings highlight the pathogenic diversity of circulating PRRSV-2 strains in Taiwan and for future experimental studies, including investigations of disease pathogenesis, therapeutic interventions, and vaccine development.

PMID 43011046
Read full article →
PubMedChemical communications (Cambridge, England)2026-11-11

In situ generated Weiss reagent-type λ3-aryliodane dication templates the self-assembly of a rare non-classical [I2Cl3]- polyinterhalide in a mixed-valence IIII/II system.

Fontana Raffaele R, Aragoni M Carla MC, Arca Massimiliano M, Puschmann Horst H et al.

The direct reaction of 1-iodo-2,6-bis(quinolin-2-yl)benzene (3) with ICl affords a rare Weiss reagent-type λ3-iodane dication, [3]2+, which directs the solid-state assembly of a non-classical polyinterhalide framework within the ionic compound [3][I2Cl3]2.

PMID 43012165
Read full article →
PubMedThe Journal of physiology2026-11-11

Increased inspiratory work exacerbates skin hypoperfusion and attenuates the pressor response during high-intensity exercise in the heat.

Koike Jun J, Fujii Naoto N

During exercise in the heat, skin vasodilatation occurs as heat loss response. Increased respiratory muscle work by inspiratory loading during high-intensity exercise causes vasoconstriction in active skeletal muscles without altering arterial blood pressure. We hypothesized that, during high-intensity exercise in the heat, inspiratory loading would induce skin vasoconstriction and thus reduce skin blood flow to maintain the pressor response associated with high-intensity exercise. Fifteen healthy young men cycled in the heat (35°C, 50% relative humidity), consisting of 14 min at 50% peak oxygen uptake ( V . O 2 peak ) followed by 3 min at 90%  V . O 2 peak . A 1 min inspiratory loading was applied 10 min into exercise at 50%  V . O 2 peak and 1 min into exercise at 90%  V . O 2 peak . The protocol without inspiratory loading was performed on a separate day as the control. Upper back skin blood flow was measured using a laser-Doppler flowmeter. Arterial blood pressure was measured using finger photoplethysmography, and skin vascular conductance was calculated as skin blood flow/mean arterial pressure. Skin blood flow decreased, whereas mean arterial pressure increased gradually during exercise at 90%  V . O 2 peak , and these responses were greater and smaller, in the inspiratory load than control (P < 0.003). Skin vascular conductance did not differ between conditions at 90%  V . O 2 peak . At 50%  V . O 2 peak , the inspiratory loading slightly reduced mean arterial pressure but did not modulate skin blood flow or skin vascular conductance. We show that increased respiratory muscle work augments the reduction in skin blood flow, whereas it attenuates the pressor response during high-intensity exercise in the heat, without modulating skin vasoconstriction. KEY POINTS: Skin vasodilatation plays a pivotal role in heat loss during exercise in the heat. Breathing, and thus respiratory muscle work, can be augmented by hyperthermia, ageing and lung or cardiovascular disease. However, whether increased respiratory muscle work influences skin vasodilatation during exercise in the heat remains unknown. Inspiratory loading, which increased the work of breathing, was applied during exercise at 50%  V . O 2 peak and at 90%  V . O 2 peak in the heat. We showed that an inspiratory load reduced skin blood flow and attenuated the increase in mean arterial pressure during exercise at 90%  V . O 2 peak without influencing skin vascular conductance. However, these effects associated with inspiratory loading were not clearly observed during exercise at 50%  V . O 2 peak . Our findings suggest that increased inspiratory muscle work may reduce heat loss associated with increases in skin blood flow and blunted pressor response during high-intensity exercise in the heat.

PMID 43012303
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about travoprost